You are here

Tetravalent bispecific fusion antibody for immunotherapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA110297-01
Agency Tracking Number: CA110297
Amount: $134,285.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2004-2
Timeline
Solicitation Year: 2004
Award Year: 2004
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
IMMUNOMEDICS, INC. 300 AMERICAN RD
MORRIS PLAINS, NJ 07950
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ZHENGXING Qu
 (973) 605-8200
 TQU@IMMUNOMEDICS.COM
Business Contact
 CYNTHIA SULLIVAN
Phone: (973) 540-9595
Email: CSULLIVAN@IMMUNOMEDICS.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Immunotherapy based on a naked monoclonal antibody (mAb), such as rituximab, has emerged as a safe and effective modality for treatment of indolent and aggressive non-Hodgkin's lymphomas (NHL) and chronic lymphocytic

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government